MAPK phosphatases as novel targets for rheumatoid arthritis

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 7, 2008, Pages 795-808

  Ralph, Jennifer A ^a   Morand, Eric F ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Arthritis; Glucocoticoids; Inflammation; MAPK; MAPK phosphatase; MKP1

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; CYTOKINE ANTIBODY; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; ORG 48762 0; SB 242235; SC 409; SD 282; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; SIGNAL TRANSDUCTION;

EID: 48949116933     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.7.795     Document Type: Review

References (116)

1. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46(8):2010-9
2. Wilder RL, Steinberg EM, Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol 1990;2(3):436-40
3. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
4. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(11):2838-46
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345(15):1098-104
6. van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001;3(1):18-26
7. Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001;40(6):699-702
8. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96(1):23-43
9. Walsh LJ, Wang CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313(7053):344-6
10. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Arthritis Rheum 2002;46(12):3115-20
11. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139(5 Pt 1):359-70
12. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18(4):128-31
13. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Ann Rev Immunol 2002;20:55-72
14. Badger AM, Roshak AK, Cook MN, et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage 2000;8(6):434-43
15. Ea HK, Uzan B, Rey C, Liote F. Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther 2005;7(5):R915-26
16. Masuko-Hongo K, Berenbaum F, Humbert L, et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004;50(9):2829-38
17. Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43(4):801-11
18. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43(11):2501-12
19. Pakozdi A, Amin MA, Haas CS, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006;8(4):R132
20. Santos LL, Lacey D, Yang Y, et al. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004;31(6):1038-43
21. Han Z, Boyle DL, Aupperle KR, et al. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291(1):124-30
22. Beyaert R, Cuenda A, Vanden Berghe W, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996;15(8):1914-23
23. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-46
24. Krause A, Holtmann H, Eickemeier S, et al. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem 1998;273(37):23681-9
25. Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54(9):2745-56
26. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15(18):2169-77
27. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275(14):10661-72
28. Tanaka K, Oda N, Iwasaka C, et al. Induction of Ets-1 in endothelial cells during reendothelialization after denuding injury. J Cell Physiol 1998;176(2):235-44
29. Jackson JR, Bolognese B, Hillegass L, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998;284(2):687-92
30. Westra J, Kuldo JM, van Rijswijk MH, et al. Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657. Int Immunopharmacol 2005;5(7-8):1259-69
31. Read MA, Whitley MZ, Gupta S, et al. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997;272(5):2753-61
32. Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFκB and p38 MAP kinase in articular chondrocytes. J Biol Chem 2006;281(26):17952-60
33. Pietersma A, Tilly BC, Gaestel M, et al. p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun 1997;230(1):44-8
34. Goebeler M, Kilian K, Gihitzer R, et al. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-α-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood 1999;93(3):857-65
35. Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43(1):175-83
36. Badger AM, Cook MN, Lark MW, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998;161(1):467-73
37. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206(1):15-21
38. Jang D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med 1998;24(9):1511-9
39. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999;1(2):94-7
40. Hegen M, Gaestel M, Nickerson-Nutter CL, et al. MAPKAP kinsse 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006:177(3):1913-7
41. Crotti TN, Smith MD, Weedon H, et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61(12):1047-54
42. Mbalaviele G, Anderson G, Jones A, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006;317(3):1044-53
43. Park CK, Kim HJ, Kwak HB, et al. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. Int Immunopharmacol 2007;7(12):1507-16
44. Lee HY, Jeon HS, Song EK, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-κB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006;54(6):1747-58
45. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FRI67653. Arthritis Rheum 2003;48(9):2670-81
46. Zwerina J, Hayer S, Redlich K, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54(2):463-72
47. Hayer S, Steiner G, Gortz B, et al. CD44 is a determinant of inflammatory bone loss. J Exp Med 2005;201(6):903-14
48. Medicherla S, Ma JY, Mangadu R, et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006;318(1):132-41
49. Mihara K, Almansa C, Smeets RL, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα. Br J Pharmacol 2008;154(1):153-64
50. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179(10):7128-36
51. Martel-Pelletier J, Mineau F, Jovanovic D, et al. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). Arthritis Rheum 1999;42(11):2399-409
52. Geppert TD, Whitehurst CE, Thompson P, Beutler B. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/ raf-1/MEK/MAPK pathway. Mol Med 1994;1(1):93-103
53. Westra J, Brouwer E, Bos R, et al. Regulation of cytokine-induced HIF-1α expression in rheumatoid synovial fibroblasts. Ann NY Acad Sci 2007;1108:340-8
54. Thiel MJ, Schaefer CJ, Lesch ME, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 2007;56(10):3347-57
55. Lin LL, Wartmann M, Lin AY, et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;72(2):269-78
56. Huh YH, Kim SH, Kim SJ, Chun JS. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem 2003;278(11):9691-7
57. Kim SJ, Jeong HJ, Moon PD, et al. The COX-2 inhibitor SC-236 exerts ann-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci 2007;81(11):863-72
58. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006;65(Suppl 3):83-8
59. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108(1):73-81
60. Han Z, Chang L, Yamanishi Y, et al. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002;46(3):818-23
61. Sundarrajan M, Boyle DL, Chabaud-Riou M, et al. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003;48(9):2450-60
62. Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 2004:172(3):1612-8
63. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297(5583):1018-23
64. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12(2):186-92
65. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997;272(27):16917-23
66. Chu Y, Solski PA, Khosravi-Far R, et al. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996;271(11):6497-501
67. Karlsson M, Mandl M, Keyse SM. Spatio-temporal regulation of mitogen-activated protein kinase (MAPK) signalling by protein phosphatases. Biochem Soc Trans 2006;34(Pt 5):842-5
68. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997;272(2):1368-76
69. Sanchez-Tillo E, Comalada M, Xaus J, et al. JNK1 Is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation. J Biol Chem 2007;282(17):12566-73
70. Lasa M, Abraham SM, Boucheron C, et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22(22):7802-11
71. Toh ML, Yang Y, Leech M, et al. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1β and glucocorticoids. Arthritis Rheum 2004; 50(10):3118-28
72. Schliess F, Heinrich S, Haussinger D. Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IIE rat hepatoma cells. Arch Biochem Biophys 1998;351(1):35-40
73. Marchetti S, Gimond C, Chambard JC, et al. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Mol Cell Biol 2005;25(2):854-64
74. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999;286(5449):2514-7
75. Stewart AE, Dowd S, Keyse SM, McDonald NQ. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat Struct Biol 1999;6(2):174-81
76. Maier JV, Brema S, Tuckermann J, et al. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 2007;21(11):2663-71
77. Zhang Y, Blattman JN, Kennedy NJ, et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 2004;430(7001):793-7
78. Zhao Q, Wang X, Nelin LD, et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006;203(1):131-40
79. Salojin KV, Owusu IB, Millerchip KA, et al. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006;176(3):1899-907
80. Hammer M, Mages J, Dietrich H, et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006;203(1):15-20
81. Chi H, Barry SP, Roth RJ, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006;103(7):2274-9
82. Zhao Q, Shepherd EG, Manson ME, et al. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005;280(9):8101-8
83. Wu JJ, Roth RJ, Anderson EJ, et al. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab 2006;4(1):61-73
84. Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203(8):1883-9
85. Jeffrey KL, Brummer T, Rolph MS, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006;7(3):274-83
86. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993;75(3):487-93
87. Dorfman K, Carrasco D, Gruda M, et al. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/ MKP-1-deficient fibroblasts. Oncogene 1996;13(5):925-31
88. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev Immunol 2007;7(3):202-12
89. Aeberli D, Yang Y, Mansell A, et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 2006;580(3):974-81
90. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005;35(12):3405-13
91. Klinman D. Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum 2003;48(3):590-3
92. Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004;50(12):3856-65
93. Huang Q, Ma Y, Adebayo A, Pope RM. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 2007;56(7):2192-201
94. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56(9):2957-67
95. Hu JH, Chen T, Zhuang ZH, et al. Feedback control of MKP-1 expression by p38. Cell Signal 2007;19(2):393-400
96. Chandrasekharan UM, Yang L, Walters A, et al. Role of CL-100, a dual specificity phosphatase, in thrombin-induced endothelial cell activation. J Biol Chem 2004;279(45):46678-85
97. Kinney CM, Chandrasekharan UM, Mavrakis L, Dicorleto PE. VEGF and thrombin induce MAP kinase phosphatase-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration. Am J Physiol Cell Physiol 2007;294(1):C241-50
98. Furst R, Schroeder T, Eilken HM, et al. MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 2007;21(1):74-80
99. Kassel O, Sancono A, Kratzschmar J, et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20(24):7108-16
100. Chen P, Li J, Barnes J, et al. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002;169(11):6408-16
101. Yang YH, Toh ML, Clyne CD, et al. Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1. J Immunol 2006;177(11):8148-53
102. Noguchi T, Metz R, Chen L, et al. Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol 1993;13(9):5195-205
103. Horsch K, de Wet H, Schuurmans MM, et al. Mkp-1/Dusp1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 2007;21(12):2929-40
104. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377(6544):68-71
105. Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42(8):1601-8
106. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43(4):827-33
107. Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 2006;45(8):937-43
108. Leech M, Lacey D, Xue JR, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003;48(7):1881-9
109. Yang H, Wu GS. p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements. Cancer Biol Ther 2004;3(12):1277-82
110. Li M, Zhou JY, Ge Y, et al. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 2003;278(42):41059-68
111. Doi M, Cho S, Yujnovsky I, et al. Light-inducible and clock-controlled expression of MAP kinase phosphatase 1 in mouse central pacemaker neurons. J Biol Rhythms 2007;22(2):127-39
112. McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum 2004;50(4):1132-45
113. Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162(6):1807-15
114. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006;25(23):3335-45
115. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191(2):229-37
116. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007;67(9):4459-66